Swedish Orphan Biovitrum AB (publ) (Sobi) announced today that the company's application for Orfadin oral suspension has been submitted to the US Food and Drug Administration (FDA). This new dosage form has been developed to facilitate the ease and accuracy of administration for Orfadin in paediatric patients as well as to increase convenience for patients and their caregivers. --- About Orfadin Orfadin is used for the treatment of hereditary tyrosinemia type 1 (HT-1), a rare genetic disorder which can cause liver failure, kidney dysfunction and neurological problems. About Sobi Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on inflammation and genetic diseases, with three late stage biological development projects within haemophilia and neonatology. We also market a portfolio of specialty and rare disease products for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2012, Sobi had total revenues of SEK 1.9 billion (€ 215 M) and about 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com. For more information - not for publication Media relations Investor relations Oskar Bosson, Head of Jörgen Winroth, Vice President, Head of Investor Communications Relations T: +46 70 410 71 80 T: +1 347-224-0819, +1 212-579-0506, +46 8 697 2135 oskar.bosson@sobi.com jorgen.winroth@sobi.com [HUG#1738708]
Sobi submits application for Orfadin® oral suspension to
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Connexa Sports Tech Faces Challenges Amidst Market Low
Connexa Sports Technologies Inc. Struggles with Market Downturn Connexa Sports Technologies Inc. (YYAI) has recently faced significant challenges, recording a 52-week low in its stock, which has fallen to $0.52. This alarming dip has highlighted the struggles of this micro-cap company, now valued at approximately $9.17 million. The past year has been especially tough for...
Continue Reading
A Comprehensive Overview of Jyske Realkredit's Upcoming Auctions
Understanding Jyske Realkredit's Auction Process On a bright February day, Jyske Realkredit is gearing up for an important event in the finance sector: their upcoming auctions aimed at refinancing operations slated for April 2025. These auctions, planned for February 4th and 5th, will focus on loans drawn from their cover pool E. What to Expect During the Auctions The...
Continue Reading
Investigation Launched into Travere Therapeutics Operations
Investigation Initiated for Travere Therapeutics, Inc. (NASDAQ: TVTX) Recently, an investigation has been launched regarding Travere Therapeutics, Inc. This inquiry is being spearheaded by the Pomerantz Law Firm, a prestigious entity in corporate litigation. Travere, known for its innovative therapies, is now facing scrutiny that necessitates the attention of its...
Continue Reading
Global Water Resources Reports Monthly Dividend for Investors
Global Water Resources Announces New Dividend Global Water Resources, Inc. (NASDAQ: GWRS), a premier company focused on water resource management, has declared a significant monthly cash dividend of $0.02533 for each common share. This translates to an annual dividend rate of $0.30396 per share, reflecting their commitment to enhancing shareholder value through consistent...
Continue Reading
Michaels Unveils Exciting Halloween Décor Ahead of Summerween
Michaels Launches Trendy Halloween Décor Collections Michaels, the go-to destination for creative enthusiasts, has announced the launch of its highly anticipated Halloween décor collections. This year marks a significant shift as the renowned craft retailer brings Halloween styles to consumers earlier than in past years. The initiative celebrates the quirky charm of...
Continue Reading